Clinical trial Recruiting at 1 site Observational

Exploring biomarkers for prediabetes and diabetes using MALDI-TOF MS technology

Official title: Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.

Run by Zhujiang Hospital · NCT06097065 · Data updated 2026-11-12

This study is trying to find new markers in blood and urine samples that can help doctors better diagnose prediabetes and diabetes in different groups of people, including pregnant women.

Quick facts

Study typeObservational
SexAll
Enrollment2860 (estimated)
SponsorZhujiang Hospital
Academic / other
Locations1 site (Guangzhou, Guangdong)
StatusRecruiting
StartedMay 20, 2022
Main results expectedDecember 31, 2025
Study endsDecember 31, 2026
Registry record updatedOctober 24, 2023
Trial IDNCT06097065 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with prediabetes, diabetes, or gestational diabetes, as well as healthy controls with normal glucose tolerance.

Probably not a fit

Patients who do not have any form of glucose metabolism disorder or those who are not pregnant may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the differences in proteomics and peptidomics between fasting serum/plasma and urine samples from individuals with normal glucose tolerance and those with prediabetes or diabetes, as well as pregnant individuals with and without gestational diabetes. By utilizing the MALDI-TOF MS platform, the study seeks to identify potential new diagnostic markers for prediabetes and diabetes. The goal is to establish a clinical predictive diagnostic model based on these differences, which could enhance the accuracy of diagnosing these conditions.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic methods for prediabetes and diabetes, allowing for earlier intervention and better management of these conditions.

How similar studies have gone: While the approach of using MALDI-TOF MS for biomarker discovery is established, the specific application to differentiate prediabetes and diabetes in this manner is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Inclusion criteria for cases:

   Non pregnant people: the remaining fasting serum/plasma and urine samples of prediabetes/diabetes patients (prediabetes: IFG: FPG 6.1-6.9mmol/L, Blood glucose 2h after meal\<7.8mmol/L(WHO); IGT: FPG\<7.0mmol/L, Blood glucose 2h after meal 7.8-11.1mmol/L(WHO); diabetes: Typical symptoms of diabetes, FPG \>= 7.0mmol/L or 75g OGTT 2h blood glucose \>= 11.1mmol/L).

   Pregnant people: the remaining fasting serum/plasma and urine samples of gestational diabetes patients (75g OGTT test FPG \>= 5.1mmol/L or 1h blood glucose \>= 10.0mmol/L or 2h blood glucose \>= 8.5mmol/L(IADPSG; ADA)).
2. Inclusion criteria of the controls were as follows:

Non pregnant people: the remaining fasting serum/plasma and urine samples of normal population for glucose tolerance test (FPG 3.9-6.1mmol/L,75g OGTT test 1h blood glucose 6.7-11.1mmol/L,75g OGTT test 2h blood glucose 3.6-7.8mmol/L).

Pregnant people: the remaining fasting serum/plasma and urine samples of people who do not meet the diagnostic criteria for gestational diabetes (3.9\<=75g OGTT test FPG\<5.1mmol/L,6.7 \<= 1h blood glucose\<10.0mmol/L,3.6\<=2h blood glucose\<8.5mmol/L).

\-

Exclusion Criteria:

Common exclusion criteria for cases and control were as follows: The sample volume of serum/plasma/urine is less than 300ul; Improper storage of samples or repeated freezing and thawing; The serum /plasma has obvious hemolysis, lipemia or jaundice.

\-

Where it's running

  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.